Institutional Case Analysis of Low Dose CT in Lung Cancer Screening for High-Risk Patient Populations
DOI:
https://doi.org/10.64149/J.Ver.7.1.50-56Keywords:
Institutional Analysis, Low Dose CT, Lung Cancer, Cancer Screening, High Risk, Diagnostic Imaging, Early DetectionAbstract
Lung cancer is the number one cause of cancer-related deaths in the world and late-stage diagnosis is one of the factors that lead to poor survival chances. In case of high-risk patients, especially chronic smokers, low-dose CT (LDCT) has become a game-changer in cancer screening as it provides the opportunity to detect small nodules in the lungs early at an early stage, and this shows a great deal of improvement in the clinical outcome. The current institutional case analysis assesses the effectiveness of the LDCT screening strategy, basing their effectiveness on the outcome of mortality reduction, uptake of screening, the diagnostic image accuracy and the impact of the institutional implementation.
The paper utilizes the secondary data of seminal trials like the NLST and NELSON, institutional reports, and published literature, and this makes it strong in terms of evidence base. Thematic analysis strategy was used to integrate common patterns in various sources, such as screening barriers, patient engagement strategies, and practices in institutions. The combination of validated quantitative results and qualitative understanding of systemic issues offers a breadth and depth of this dual methodology.
Findings prove that LDCT minimizes the deaths of lung cancer by 2024 percent, doubles the stage I diagnoses, and increases the survival rate when made a part of the institutional practice. Nevertheless, adoption is still very low, with less than 20 per cent of those who are eligible being screened, which is indicative of inherent system barriers, including inequity in access and perceptions of patients. The success of a program is heavily dependent on the institutional implementation, where standardised imaging protocols with patient navigation services enhance the quality of diagnostic testing and attendance.
This discussion has determined that LDCT is an important breakthrough in lung cancer screening; however, it can only achieve its full potentials when it goes beyond institutional and systemic obstacles to exploit the opportunities presented by high risk groups.



